Ionis Pharmaceuticals (FRA:ISI) Cyclically Adjusted Book per Share: €4.57 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ISI Ionis Pharmaceuticals Inc FRA:ISI
72 GF Score
Price €49.53
GF Value €48.38
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Cyclically Adjusted Book per Share?

Ionis Pharmaceuticals FRA:ISI -1.84% 72 Cyclically Adjusted Book per Share is €4.57 as of Mar. 2026. GuruFocus rates FRA:ISI with a GF Score™ of 72/100 and a GF Value™ of €48.38 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Ionis Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €2.562. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.57 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ionis Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 5.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 2.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 5.40% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Ionis Pharmaceuticals was 20.90% per year. The lowest was -21.40% per year. And the median was 7.05% per year.

As of today (2026-07-15), Ionis Pharmaceuticals's current stock price is €49.53. Ionis Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €4.57. Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 10.84.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ionis Pharmaceuticals was 29.73. The lowest was 5.22. And the median was 13.41.


Ionis Pharmaceuticals  (FRA:ISI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=49.53/4.57
=10.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Ionis Pharmaceuticals was 29.73. The lowest was 5.22. And the median was 13.41.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Ionis Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Ionis Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Cyclically Adjusted Book per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.98 4.63 4.56 5.00 4.53

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.88 4.48 4.41 4.53 4.57

FRA:ISI vs EXEL, BBIO, AXSM: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:ISI
72GF Score
Ionis Pharmaceuticals Inc FRA:ISI
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ionis Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.562/330.2130*330.2130
=2.562

Current CPI (Mar. 2026) = 330.2130.

Ionis Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.819 241.018 1.122
201609 1.027 241.428 1.405
201612 0.776 241.432 1.061
201703 1.523 243.801 2.063
201706 1.545 244.955 2.083
201709 2.073 246.819 2.773
201712 1.900 246.524 2.545
201803 1.948 249.554 2.578
201806 4.345 251.989 5.694
201809 4.428 252.439 5.792
201812 6.679 251.233 8.779
201903 7.655 254.202 9.944
201906 8.002 256.143 10.316
201909 8.628 256.759 11.096
201912 9.434 256.974 12.123
202003 8.838 258.115 11.307
202006 8.767 257.797 11.230
202009 8.400 260.280 10.657
202012 4.353 260.474 5.518
202103 4.057 264.877 5.058
202106 3.429 271.696 4.168
202109 3.194 274.310 3.845
202112 4.837 278.802 5.729
202203 4.545 287.504 5.220
202206 4.167 296.311 4.644
202209 4.227 296.808 4.703
202212 3.807 296.797 4.236
202303 3.178 301.836 3.477
202306 2.761 305.109 2.988
202309 2.061 307.789 2.211
202312 2.457 306.746 2.645
202403 1.870 312.332 1.977
202406 1.678 314.175 1.764
202409 3.782 315.301 3.961
202412 3.558 315.605 3.723
202503 2.767 319.799 2.857
202506 3.440 322.561 3.522
202509 3.267 324.800 3.321
202512 2.558 324.054 2.607
202603 2.562 330.213 2.562

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €4.57 mean?
Ionis Pharmaceuticals (FRA:ISI) has a Cyclically Adjusted Book per Share of €4.57 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Ionis Pharmaceuticals' current Cyclically Adjusted Book per Share is €4.57. Overall, Ionis Pharmaceuticals has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Cyclically Adjusted Book per Share compare to EXEL and BBIO?
Ionis Pharmaceuticals' Cyclically Adjusted Book per Share of €4.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Cyclically Adjusted Book per Share is €4.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (FRA:ISI) is currently considered Fairly Valued. The stock's GF Value™ is €48.38, compared to a current price of €49.53 — trading 2.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is €4.57. Ionis Pharmaceuticals' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (FRA:ISI), the current Cyclically Adjusted Book per Share is €4.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €49.53 is trading 2.4% above its estimated GF Value™ of €48.38. GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:ISI:

  • Cyclically Adjusted Book per Share: €4.57
  • GF Value™: €48.38 vs. price of €49.53 (2.4% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA1IONS:Italy0JDI:UK
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
72GF Score

Get the complete analysis for FRA:ISI

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€49.53
Price
€48.38
GF Value